{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:40:09Z","timestamp":1749940809799,"version":"3.41.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>Cannabidiol is a phytocannabinoid that lacks the psychotomimetic properties of \u03949-tetrahydrocannabinol (THC), the main psychoactive <jats:italic toggle=\"yes\">Cannabis sativa<\/jats:italic> component. Cannabidiol has several potential therapeutic properties, including anxiolytic, antidepressant, and antipsychotic; however, cannabidiol has low oral bioavailability, which can limit its clinical use. Here, we investigated if two cannabidiol analogs, HU-502 and HU-556, would be more potent than cannabidiol in behavioral tests predictive of anxiolytic, antidepressant, and antipsychotic effects. Different doses (0.01\u20133\u2005mg\/kg; intraperitoneally) of HU-556 and HU-502 were tested in male Swiss mice submitted to the elevated plus maze (EPM), forced swimming test (FST), and amphetamine-induced-prepulse inhibition (PPI) disruption and hyperlocomotion. Cannabidiol is effective in these tests at a dose range of 15\u201360\u2005mg\/kg in mice. We also investigated if higher doses of HU-556 (3 and 10\u2005mg\/kg) and HU-502 (10\u2005mg\/kg) produced the cannabinoid tetrad (hypolocomotion, catalepsy, hypothermia, and analgesia), which is induced by THC-like compounds. HU-556 (0.1 and 1\u2005mg\/kg) increased the percentage of open arm entries (but not time) in the EPM, decreased immobility time in the FST, and attenuated amphetamine-induced PPI disruption. HU-502 (1 and 3\u2005mg\/kg) decreased amphetamine-induced hyperlocomotion and PPI impairment. HU-556, at high doses, caused catalepsy and hypolocomotion, while HU-502 did not. These findings suggest that similar to cannabidiol, HU-556 could induce anxiolytic, antidepressant, and antipsychotic-like effects and that HU-502 has antipsychotic properties. These effects were found at a dose range devoid of cannabinoid tetrad effects.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000727","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T15:01:54Z","timestamp":1683903714000},"page":"213-224","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Behavioral effects induced by the cannabidiol analogs HU-502 and HU-556"],"prefix":"10.1097","volume":"34","author":[{"given":"D\u00e9bora A. E.","family":"Colodete","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole R.","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Francisco C.","family":"Pedrazzi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences and Behavioral Sciences, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoela V.","family":"Foga\u00e7a","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isadora","family":"Cortez","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine A.","family":"Del-Bel","sequence":"additional","affiliation":[{"name":"Department of Physiology, Ribeir\u00e3o Preto Dentistry School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviva","family":"Breuer","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Natural Products, Hebrew University Medical Faculty, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Mechoulam","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe V.","family":"Gomes","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Natural Products, Hebrew University Medical Faculty, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco S.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients.","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"42111","DOI":"10.4088\/JCP.21m14130","article-title":"Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial.","volume":"83","author":"Berger","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br J Pharmacol"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-2999(03)01274-3","article-title":"The mouse light\/dark box test.","volume":"463","author":"Bourin","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"e0158779","DOI":"10.1371\/journal.pone.0158779","article-title":"Fluorinated cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects.","volume":"11","author":"Breuer","year":"2016","journal-title":"PLoS One"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","article-title":"Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats.","volume":"199","author":"Campos","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.pnpbp.2009.08.017","article-title":"Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids.","volume":"33","author":"Campos","year":"2009","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatry"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.","volume":"367","author":"Campos","year":"2012","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1017\/S1461145712001502","article-title":"The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.","volume":"16","author":"Campos","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"R11-20250614","first-page":"182","article-title":"Medical letter on drugs and therapeutics.","volume":"60","year":"2018"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/biom12081084","article-title":"Minor phytocannabinoids: a misleading name but a promising opportunity for biomedical research.","volume":"12","author":"Caprioglio","year":"2022","journal-title":"Biomolecules"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FBP.0b013e32833b33c5","article-title":"Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors.","volume":"21","author":"Casarotto","year":"2010","journal-title":"Behav Pharmacol"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0149-7634(01)00011-2","article-title":"A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field.","volume":"25","author":"Choleris","year":"2001","journal-title":"Neurosci Biobehav Rev"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs.","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0278-5846(97)00184-X","article-title":"Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice.","volume":"22","author":"Curzon","year":"1998","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R20-20250614","first-page":"2613","article-title":"Hyponeophagia: a measure of anxiety in the mouse.","volume":"51","author":"Deacon","year":"2011","journal-title":"J Vis Exp"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/schbul\/sbp132","article-title":"Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.","volume":"36","author":"van den Buuse","year":"2010","journal-title":"Schizophr Bull"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of \u03949-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.","volume":"95","author":"El-Alfy","year":"2010","journal-title":"Pharmacol Biochem Behav"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuropharm.2018.03.001","article-title":"The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling.","volume":"135","author":"Foga\u00e7a","year":"2018","journal-title":"Neuropharmacology"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"970210","DOI":"10.3389\/fpsyt.2022.970210","article-title":"Factors influencing the outcome of integrated therapy approach in schizophrenia: a narrative review of the literature.","volume":"13","author":"Giordano","year":"2022","journal-title":"Front Psychiatry"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00213-010-2036-z","article-title":"The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors.","volume":"213","author":"Gomes","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"R28-20250614","first-page":"pyu041","article-title":"Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice.","volume":"18","author":"Gomes","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02244012","article-title":"Antianxiety effect of cannabidiol in the elevated plus-maze.","volume":"100","author":"Guimar\u00e3es","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0306-3623(94)90027-2","article-title":"Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze.","volume":"25","author":"Guimar\u00e3es","year":"1994","journal-title":"Gen Pharmacol"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00504983","article-title":"Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of \u2018fear\u2019-motivated behaviour.","volume":"327","author":"Handley","year":"1984","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","article-title":"Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective.","volume":"73","author":"Hashimoto","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: state of the art and new directions.","volume":"27","author":"Howes","year":"2022","journal-title":"Mol Psychiatry"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","article-title":"Cannabidiol interferes with the effects of delta 9 \u2013 tetrahydrocannabinol in man.","volume":"28","author":"Karniol","year":"1974","journal-title":"Eur J Pharmacol"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1007\/s00213-014-3481-x","article-title":"CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice.","volume":"231","author":"Khella","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0091-3057(86)90107-3","article-title":"Sensitization to amphetamine and tolerance to cocaine and phencyclidine stimulation in mice.","volume":"25","author":"Kokkinidis","year":"1986","journal-title":"Pharmacol Biochem Behav"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1358\/dot.2019.55.3.2909248","article-title":"Cannabidiol as adjunctive treatment of seizures associated with Lennox\u2013Gastaut syndrome and Dravet syndrome.","volume":"55","author":"Lattanzi","year":"2019","journal-title":"Drugs Today"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fphar.2014.00010","article-title":"Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain.","volume":"5","author":"Levin","year":"2014","journal-title":"Front Pharmacol"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fnbeh.2014.00208","article-title":"Mechanisms underlying the antidepressant response and treatment resistance.","volume":"8","author":"Levinstein","year":"2014","journal-title":"Front Behav Neurosci"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.","volume":"41","author":"Linares","year":"2019","journal-title":"Br J Psychiatry"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors.","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"key":"R43-20250614","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/BF00177912","article-title":"The use of a plus-maze to measure anxiety in the mouse.","volume":"92","author":"Lister","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"R44-20250614","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.npp.1300838","article-title":"Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice.","volume":"31","author":"Long","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R45-20250614","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/BF00212846","article-title":"Dopaminergic stimulation disrupts sensorimotor gating in the rat.","volume":"94","author":"Mansbach","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"R46-20250614","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1126\/science.168.3936.1159","article-title":"Marihuana chemistry.","volume":"168","author":"Mechoulam","year":"1970","journal-title":"Science"},{"key":"R47-20250614","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2005.02.040","article-title":"Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice.","volume":"512","author":"Moreira","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"R48-20250614","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728214.2015.1049996","article-title":"Emerging drugs for the treatment of anxiety.","volume":"20","author":"Murrough","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"key":"R49-20250614","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0361-9230(94)00276-7","article-title":"Amphetamine sensitivity in open-field activity vs. the prepulse inhibition paradigm.","volume":"37","author":"Ott","year":"1995","journal-title":"Brain Res Bull"},{"key":"R50-20250614","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002130100818","article-title":"Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats.","volume":"156","author":"Paab\u00f8l Andersen","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"R51-20250614","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.pharmtox.41.1.443","article-title":"Metabolism of fluorine-containing drugs.","volume":"41","author":"Park","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R52-20250614","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s00213-015-3945-7","article-title":"Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.","volume":"232","author":"Pedrazzi","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"R53-20250614","doi-asserted-by":"crossref","first-page":"110352","DOI":"10.1016\/j.pnpbp.2021.110352","article-title":"Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum.","volume":"111","author":"Pedrazzi","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R54-20250614","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1523\/JNEUROSCI.3387-15.2016","article-title":"Cannabidiol counteracts amphetamine-induced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR\/p70S6 kinase signaling pathway.","volume":"36","author":"Renard","year":"2016","journal-title":"J Neurosci"},{"key":"R55-20250614","doi-asserted-by":"crossref","first-page":"104749","DOI":"10.1016\/j.phrs.2020.104749","article-title":"Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors.","volume":"156","author":"Rodrigues da Silva","year":"2020","journal-title":"Pharmacol Res"},{"key":"R56-20250614","doi-asserted-by":"crossref","first-page":"108577","DOI":"10.1016\/j.yebeh.2022.108577","article-title":"A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development.","volume":"128","author":"Samanta","year":"2022","journal-title":"Epilepsy Behav"},{"key":"R57-20250614","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose.","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl Psychiatry"},{"key":"R58-20250614","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0361-9230(99)00036-2","article-title":"Amphetamine dose dependently disrupts prepulse inhibition of the acoustic startle response in rats within a narrow time window.","volume":"48","author":"Sills","year":"1999","journal-title":"Brain Res Bull"},{"key":"R59-20250614","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pnpbp.2017.07.012","article-title":"Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative.","volume":"79","author":"Silva","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R60-20250614","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neuron.2022.12.022","article-title":"THC and CBD: similarities and differences between siblings.","volume":"111","author":"Stella","year":"2023","journal-title":"Neuron"},{"key":"R61-20250614","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1111\/bph.15185","article-title":"A systematic review of minor phytocannabinoids with promising neuroprotective potential.","volume":"177","author":"Stone","year":"2020","journal-title":"Br J Pharmacol"},{"key":"R62-20250614","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/sj.npp.1300086","article-title":"Amphetamine effects on prepulse inhibition across-species: replication and parametric extension.","volume":"28","author":"Swerdlow","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R63-20250614","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial.","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"key":"R64-20250614","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nprot.2007.44","article-title":"The use of the elevated plus maze as an assay of anxiety-related behavior in rodents.","volume":"2","author":"Walf","year":"2007","journal-title":"Nat Protocols"},{"key":"R65-20250614","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"},{"key":"R66-20250614","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br J Pharmacol"},{"key":"R67-20250614","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"key":"R68-20250614","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","article-title":"Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.","volume":"39","author":"Zuardi","year":"2006","journal-title":"Braz J Med Biol Res"},{"key":"R69-20250614","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0269881106060967","article-title":"Cannabidiol monotherapy for treatment-resistant schizophrenia.","volume":"20","author":"Zuardi","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R70-20250614","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2017.00259","article-title":"Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life.","volume":"8","author":"Zuardi","year":"2017","journal-title":"Front Pharmacol"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:00:39Z","timestamp":1749938439000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000727","relation":{},"ISSN":["0955-8810"],"issn-type":[{"type":"print","value":"0955-8810"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}